- 询价
- SouthernBiotech
- 6110-05
- 2025年07月08日
- ELISA, IHC-FS, IHC-PS, WB
- 驴
企业认证
相关产品推荐更多 >
山羊抗兔igg (H + L)，小鼠/人ads-sprd-Goat Anti-Rabbit IgG(H+L), Mouse/Human ads-SPRD
询价山羊抗小鼠IgG2b，人ads-sprd-Goat Anti-Mouse IgG2b, Human ads-SPRD
询价山羊F(ab')2抗大鼠IgG(H + L)，小鼠ads-pe/TXRDR-Goat F(ab')2 Anti-Rat IgG(H+L), Mouse ads-PE/TXRD
询价驴抗兔igg (H + L)，小鼠/大鼠/人SP ads-CY5-Donkey Anti-Rabbit IgG(H+L), Mouse/Rat/Human SP ads-CY5
询价驴F(ab')2抗兔igg (H + L)，小鼠/大鼠/人SP ads-A-Donkey F(ab')2 Anti-Rabbit IgG(H+L), Mouse/Rat/Human SP ads-AP
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
IgY
- 保存条件：
2-8°C
- 保质期：
2年
- 级别：
科研级别
- 库存：
100
- 供应商：
艾美捷科技
- 宿主：
驴
- 应用范围：
ELISA, IHC-FS, IHC-PS, WB
- 抗体英文名：
Goat Anti-Turkey IgY(H+L)-HRP
- 抗体名：
Goat Anti-Turkey IgY(H+L)-HRP
山羊抗火鸡IgY(H + L)-HRP，Goat Anti-Turkey IgY(H+L)-HRP，山羊抗火鸡IgY(H + L)-HRP,Goat Anti-Turkey IgY(H+L)-HRP
产品名称：山羊抗火鸡IgY(H + L)-HRP-Goat Anti-Turkey IgY(H+L)-HRP
产品货号：6110-05
产品规格：1.0mL
应用类型：ELISA, IHC-FS, IHC-PS, WB
用于ELISA、免疫组织化学和蛋白质印迹分析的山羊抗火鸡IgY(H + L)-HRP抗体。
山羊抗火鸡IgY(H + L)-HRP-Goat Anti-Turkey IgY(H+L)-HRP2-8°C
点击：山羊抗火鸡IgY(H + L)-HRP-Goat Anti-Turkey IgY(H+L)-HRP更多SouthernBiotech产品信息价格，货期，产品说明，百度搜“艾美捷科技”进入官网网站，查看具体产品且快速下单。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验E L I S A w i t h p l a t e l e t s
OUTLINE This modification of qualitative ELISA (Enzyme-Linked Immunosorbent Assay) is used for either screening detection of anti-platelet antibodies or for detection of platelet-associated Ig (PAIg) (shown here). PROTOCOL
Anti-Factor H Autoantibodies Assay
of autoantibodies directed against Factor H (FH), the main plasmatic alternative complement pathway regulatory protein. Their presence induces an acquired functional FH deficiency. The anti-FH autoantibodies screening must be performed at the very onset
Adenoviral-Mediated Anti-H-ras Ribozyme for the Treatment of Bladder Cancer
Bladder cancer is the fifth most common malignancy, demonstrated by the approx 52,900 patients that will be diagnosed in the United States in 1996 (1 ). Around 15–20% of these patients will be characterized by muscle invasion or node posmve
技术资料暂无技术资料 索取技术资料
